New studies indicate that biomarkers predict therapy responsMarch 03, 2023 - New studies are demonstrating that biomarkers are incumbent to predicting therapy response and suggest potential strategies involving the remodeling of the tumor microenvironment (TME) to overcome immunotherapy resistance.
https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-023-01164-9
As background, the tumor microenvironment (TME) plays an important role in tumor development, progression, metastasis, and drug resistance.
ONCY has demonstrated that pelareorep has the ability to:
(1) remodel an otherwise hypoxic TME,
(2)"prime" the innate and adaptive immune system,
(3) make the tumor microenvironment (TME) conducive for the sequential addition of PD-(L)1 immune checkpoint inhibitors,
(4) enhance the upregulation of of PD-1 receptors on the cancer cell surface thus turns cold tumors into "hot" tumors,
(5) overcome T-cell exhaustion, I/O, and drug resistance,
(6) implement AWARE-1 study identified clinical biomarkers to effectively determine which patients will positively respond to pelareorep + PD-(L)1 immune checkpoint inhibitor therapy and which patients may not.